[go: up one dir, main page]

PE20091217A1 - Formas cristalinas de n-(terc-butoxicarbonil)-3-metil-l-valil-(4r)-4-((7-cloro-4-metoxi-1-isoquinolinil)oxi)-n-((1r,2s)-1-((ciclopropilsulfonil)carbamoil)-2-vinilciclopropil)-l-prolinamida - Google Patents

Formas cristalinas de n-(terc-butoxicarbonil)-3-metil-l-valil-(4r)-4-((7-cloro-4-metoxi-1-isoquinolinil)oxi)-n-((1r,2s)-1-((ciclopropilsulfonil)carbamoil)-2-vinilciclopropil)-l-prolinamida

Info

Publication number
PE20091217A1
PE20091217A1 PE2008002161A PE2008002161A PE20091217A1 PE 20091217 A1 PE20091217 A1 PE 20091217A1 PE 2008002161 A PE2008002161 A PE 2008002161A PE 2008002161 A PE2008002161 A PE 2008002161A PE 20091217 A1 PE20091217 A1 PE 20091217A1
Authority
PE
Peru
Prior art keywords
crystalline forms
cyclopropylsulfonil
butoxicarbonyl
carbamoil
terc
Prior art date
Application number
PE2008002161A
Other languages
English (en)
Inventor
Robert Kevin Perrone
Chenchi Wang
William Ying
Anne I Song
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40467309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091217(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20091217A1 publication Critical patent/PE20091217A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A FORMAS CRISTALINAS DE N-(TERC-BUTOXICARBONIL)-3-METIL-L-VALIL-(4R)-4-((7-CLORO-4-METOXI-1-ISOQUINOLINIL)OXI)-N-((1R,2S)-1-((CICLOPROPILSULFONIL)CARBAMOIL)-2-VINILCICLOPROPIL)-L-PROLINAMIDA, TAL COMO i) LA FORMA H-1 CON PICOS CARACTERISTICOS EN EL PATRON DE DIFRACCION DE RAYOS X POR CRISTALES FINOS EN VALORES DE DOS THETA DE 6,3 ± 0,1; 7,1 ± 0,1; 9,4 ± 0,1; 10,3 ± 0,1; 12,7 ± 0,1; 13,8 ± 0,1; 17,5 ± 0,1; ENTRE OTROS; ii) LA FORMA T1F-1/2 CON PICOS CARACTERISTICOS EN EL PATRON DE DIFRACCION DE RAYOS X POR CRISTALES FINOS EN VALORES DE DOS THETA DE 7,3 ± 0,1; 9,1 ± 0,1; 10,0 ± 0,1; 10,6 ± 0,1; 11,1 ± 0,1; 12,3 ± 0,1; 15,6 ± 0,1; ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA QUE CONTIENE DICHAS FORMAS CRISTALINAS Y OPCIONALMENTE OTRO COMPUESTO TAL COMO INTERLEUCINA 2, RIBAVIRINA, ENTRE OTROS. DICHAS FORMAS CRISTALINAS SON UTILES EN EL TRATAMIENTO DE LA HEPATITIS C
PE2008002161A 2007-12-21 2008-12-19 Formas cristalinas de n-(terc-butoxicarbonil)-3-metil-l-valil-(4r)-4-((7-cloro-4-metoxi-1-isoquinolinil)oxi)-n-((1r,2s)-1-((ciclopropilsulfonil)carbamoil)-2-vinilciclopropil)-l-prolinamida PE20091217A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1579507P 2007-12-21 2007-12-21

Publications (1)

Publication Number Publication Date
PE20091217A1 true PE20091217A1 (es) 2009-08-14

Family

ID=40467309

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2017000076A PE20170534A1 (es) 2007-12-21 2008-12-19 Formas cristalinas de n-(terc-butoxicarbonil)-3-metil-l-valil-(4r)-4-((7-cloro-4-metoxi-1-isoquinolinil)oxi)-n-((1r,2s)-1-((ciclopropilsulfonil)carbamoil)-2-vinilciclopropil)-l-prolinamida
PE2008002161A PE20091217A1 (es) 2007-12-21 2008-12-19 Formas cristalinas de n-(terc-butoxicarbonil)-3-metil-l-valil-(4r)-4-((7-cloro-4-metoxi-1-isoquinolinil)oxi)-n-((1r,2s)-1-((ciclopropilsulfonil)carbamoil)-2-vinilciclopropil)-l-prolinamida
PE2013000341A PE20131130A1 (es) 2007-12-21 2008-12-19 Formas cristalinas de n-(terc-butoxicarbonil)-3-metil-l-valil-(4r)-4-((7-cloro-4-metoxi-1-isoquinolinil)oxi)-n-((1r,2s)-1-((ciclopropilsulfonil)carbamoil)-2-vinilciclopropil)-l-prolinamida

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2017000076A PE20170534A1 (es) 2007-12-21 2008-12-19 Formas cristalinas de n-(terc-butoxicarbonil)-3-metil-l-valil-(4r)-4-((7-cloro-4-metoxi-1-isoquinolinil)oxi)-n-((1r,2s)-1-((ciclopropilsulfonil)carbamoil)-2-vinilciclopropil)-l-prolinamida

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2013000341A PE20131130A1 (es) 2007-12-21 2008-12-19 Formas cristalinas de n-(terc-butoxicarbonil)-3-metil-l-valil-(4r)-4-((7-cloro-4-metoxi-1-isoquinolinil)oxi)-n-((1r,2s)-1-((ciclopropilsulfonil)carbamoil)-2-vinilciclopropil)-l-prolinamida

Country Status (18)

Country Link
US (2) US8202996B2 (es)
EP (1) EP2231639B1 (es)
JP (1) JP5566907B2 (es)
KR (1) KR101560428B1 (es)
CN (3) CN101903371B (es)
AR (2) AR069886A1 (es)
AU (1) AU2008343423B2 (es)
CL (1) CL2008003849A1 (es)
DK (1) DK2231639T3 (es)
ES (1) ES2536409T3 (es)
HR (1) HRP20150458T1 (es)
MX (1) MX336329B (es)
PE (3) PE20170534A1 (es)
PL (1) PL2231639T3 (es)
PT (1) PT2231639E (es)
SI (1) SI2231639T1 (es)
TW (1) TWI496573B (es)
WO (1) WO2009085659A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
US8202996B2 (en) * 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
DE102008019907A1 (de) 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
US20090285774A1 (en) * 2008-05-15 2009-11-19 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20090285773A1 (en) * 2008-05-15 2009-11-19 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
EP2300491B1 (en) * 2008-05-29 2016-01-06 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US7964560B2 (en) * 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
DE102008028905A1 (de) 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
MY160526A (en) 2008-12-22 2017-03-15 Merck Patent Gmbh Novel polymorphic forms of 6-(1-methyl-1h-pyrazol-4-yl)-2-{3-[5-(2-morpholin-4-yl-ethoxy)-pyrimidin-2-yl]-benzyl}-2h-pyridazin-3-one dihydrogenphosphate and processes of manufacturing thereof
US8415374B2 (en) * 2009-10-12 2013-04-09 Bristol-Myers Squibb Company Combinations of hepatitis C virus inhibitors
CA2822556A1 (en) 2010-12-30 2012-07-05 Enanta Pharmaceuticals, Inc Macrocyclic hepatitis c serine protease inhibitors
CN103380132B (zh) 2010-12-30 2016-08-31 益安药业 菲啶大环丙型肝炎丝氨酸蛋白酶抑制剂
US10920242B2 (en) 2011-02-25 2021-02-16 Recombinetics, Inc. Non-meiotic allele introgression
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
ES2650223T3 (es) * 2011-05-27 2018-01-17 Bristol-Myers Squibb Company Tripéptidos que incorporan deuterio como inhibidores del virus de la hepatitis C
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2013201532B2 (en) 2011-10-21 2014-10-02 Abbvie Ireland Unlimited Company Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
EA201490837A1 (ru) 2011-10-21 2014-11-28 Эббви Инк. Способы лечения hcv, включающие по меньшей мере два противовирусных агента прямого действия, рибавирин, но не интерферон
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
CN102595458B (zh) * 2012-03-16 2014-04-09 电子科技大学 一种分布式多径路由修复方法
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
SI2909205T1 (sl) 2012-10-19 2017-02-28 Bristol-Myers Squibb Company 9-metil substituiran heksadekahidrociklopropa(e)pirolo(1,2-A)(1,4)diazaciklopentadecinil karbamat derivati kot nestrukturalni 3 (NS3) proteazni inhibitorji za zdravljenje hepatitis C virusnih infekcij
EP2914598B1 (en) 2012-11-02 2017-10-18 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014070964A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP6342922B2 (ja) 2013-03-07 2018-06-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤
BR112015021768A2 (pt) 2013-03-15 2016-02-02 Gilead Sciences Inc inibidores do vírus da hepatite c
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
CN106459145A (zh) * 2014-06-25 2017-02-22 百时美施贵宝公司 丙型肝炎病毒抑制剂
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
IL280880B2 (en) 2018-08-27 2025-04-01 Regeneron Pharma Using Raman Spectroscopy in Downstream Purification
WO2022055916A1 (en) * 2020-09-09 2022-03-17 Merck Sharp & Dohme Corp. Process for preparing sugammadex

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0475255A3 (en) 1990-09-12 1993-04-14 F. Hoffmann-La Roche Ag Process for the preparation of optically pure (s)-alpha-((tert-butylsulfonyl)methyl)hydro cinnamic acid
DE69709671T2 (de) 1996-10-18 2002-08-22 Vertex Pharmaceuticals Inc., Cambridge Inhibitoren von serinproteasen, insbesondere von ns3-protease des hepatitis-c-virus
JP4452401B2 (ja) 1997-08-11 2010-04-21 ベーリンガー インゲルハイム （カナダ） リミテッド Ｃ型肝炎ウイルス阻害ペプチドアナログ
EP1003775B1 (en) 1997-08-11 2005-03-16 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor peptides
AR022061A1 (es) 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US7244721B2 (en) 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
ATE461207T1 (de) 2000-07-21 2010-04-15 Schering Corp Peptide als inhibitoren der ns3-serinprotease des hepatitis c virus
PE20020707A1 (es) 2000-11-20 2002-08-11 Bristol Myers Squibb Co Compuestos tripeptidicos como inhibidores de la proteasa ns3 del virus de hepatitis c
WO2003039517A1 (en) * 2001-11-02 2003-05-15 Sandoz Inc. Process for preparing quick dissolving, high loading ribavirin compositions
US6867185B2 (en) 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
CA2369711A1 (en) 2002-01-30 2003-07-30 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis c virus
CA2369970A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
CA2370396A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
US6828301B2 (en) 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
MY140680A (en) * 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
DE60324552D1 (en) 2002-05-20 2008-12-18 Bristol Myers Squibb Co Substituierte cycloalkyl p1' hepatitis c virus inhibitoren
US20060199773A1 (en) 2002-05-20 2006-09-07 Sausker Justin B Crystalline forms of (1R,2S)-N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenyl-cyclopropanecarboxamide, monopotassium salt
DE60334205D1 (en) 2002-05-20 2010-10-28 Bristol Myers Squibb Co Heterocyclische sulfonamid-hepatitis-c-virus-hemmer
PL215228B1 (pl) 2002-05-20 2013-11-29 Bristol Myers Squibb Co Zwiazki tripeptydowe, ich zastosowanie i kompozycja farmaceutyczna je zawierajaca oraz jej zastosowanie
US20040033959A1 (en) 2002-07-19 2004-02-19 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceutical compositions for hepatitis C viral protease inhibitors
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
US7601709B2 (en) 2003-02-07 2009-10-13 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis C serine protease inhibitors
CN1771050A (zh) 2003-02-07 2006-05-10 益安药业 丙型肝炎丝氨酸蛋白酶的大环抑制剂
WO2004101605A1 (en) 2003-03-05 2004-11-25 Boehringer Ingelheim International Gmbh Hepatitis c inhibiting compounds
EP1599496B1 (en) 2003-03-05 2010-11-03 Boehringer Ingelheim International GmbH Hepatitis c inhibitor peptide analogs
KR20050108420A (ko) 2003-04-02 2005-11-16 베링거 인겔하임 인터내셔날 게엠베하 Ｃ형 간염 바이러스 프로테아제 억제제를 위한 약제학적조성물
ATE422895T1 (de) 2003-04-16 2009-03-15 Bristol Myers Squibb Co Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus
EP2143727B1 (en) 2003-04-18 2015-01-21 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
EA009295B1 (ru) 2003-05-21 2007-12-28 Бёрингер Ингельхайм Интернациональ Гмбх Соединения в качестве ингибиторов вируса гепатита с
WO2004113365A2 (en) 2003-06-05 2004-12-29 Enanta Pharmaceuticals, Inc. Hepatitis c serine protease tri-peptide inhibitors
US7125845B2 (en) 2003-07-03 2006-10-24 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis C serine protease inhibitors
JP2007505071A (ja) * 2003-09-11 2007-03-08 エフ．ホフマン−ラ　ロシュ　アーゲー 結晶多形性ヌクレオシド化合物
RS20060197A (sr) 2003-09-22 2008-09-29 Boehringer Ingelheim International Gmbh., Makrociklični peptidi koji su aktivni protiv hepatitisa c virusa
AU2004282148A1 (en) 2003-10-10 2005-04-28 Vertex Pharmaceuticals Incoporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
RS20110578A3 (en) 2003-10-14 2016-02-29 F. Hoffmann-La Roche Ltd MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULPHONAMIDES AS HCV REPLICATION INHIBITORS
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN1902216A (zh) 2003-11-20 2007-01-24 先灵公司 丙肝病毒ns3蛋白酶的去肽化抑制剂
US7309708B2 (en) 2003-11-20 2007-12-18 Birstol-Myers Squibb Company Hepatitis C virus inhibitors
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP4682155B2 (ja) 2004-01-21 2011-05-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎ウイルスに対して活性な大環状ペプチド
DE602005017582D1 (en) 2004-01-30 2009-12-24 Medivir Ab Hcv ns-3 serine protease inhibitoren
BRPI0508867A (pt) 2004-03-15 2007-09-04 Boehringer Ingelheim Int processo para a preparação de compostos macrocìclicos
BRPI0509467A (pt) 2004-03-30 2007-09-11 Intermune Inc compostos macrocìclicos como inibidores de replicação viral
WO2006016930A2 (en) 2004-05-14 2006-02-16 Intermune, Inc. Methods for treating hcv infection
EP1753775B1 (en) 2004-05-25 2012-12-26 Boehringer Ingelheim International GmbH Process for preparing acyclic hcv protease inhibitors
EP1763531A4 (en) 2004-06-28 2009-07-01 Boehringer Ingelheim Int ANALOGUE OF HEPATITIS-C INHIBITING PEPTIDES
EP1778702B1 (en) 2004-07-16 2011-07-13 Gilead Sciences, Inc. Antiviral compounds
ATE512971T1 (de) 2004-07-20 2011-07-15 Boehringer Ingelheim Int Peptidanaloga als hepatitis c-hemmer
UY29016A1 (es) 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
CN101068828A (zh) 2004-08-27 2007-11-07 先灵公司 用作丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的酰基磺酰胺化合物
JP2008513454A (ja) 2004-09-17 2008-05-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 大環状ｈｃｖプロテアーゼインヒビターの調製方法
WO2007001406A2 (en) 2004-10-05 2007-01-04 Chiron Corporation Aryl-containing macrocyclic compounds
US20070249637A1 (en) 2004-10-21 2007-10-25 Collins Michael R Inhibitors Of Hepatitis C Virus Protease, And Compositions And Treatments Using The Same
US7323447B2 (en) 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
DK1863833T3 (da) 2005-03-08 2013-12-02 Boehringer Ingelheim Int Fremgangsmåde til fremstilling af makrocykliske forbindelser
JP4705164B2 (ja) 2005-05-02 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション Ｈｃｖｎｓ３プロテアーゼ阻害剤
US7592336B2 (en) 2005-05-10 2009-09-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20070021351A1 (en) 2005-06-02 2007-01-25 Schering Corporation Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor
US20060276405A1 (en) 2005-06-02 2006-12-07 Schering Corporation Methods for treating hepatitis C
US20060276406A1 (en) 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis C virus
WO2006130666A2 (en) 2005-06-02 2006-12-07 Schering Corporation Medicaments and methods combining a hcv protease inhibitor and an akr competitor
AR055198A1 (es) 2005-06-02 2007-08-08 Schering Corp Formulaciones farmaceuticas y metodos de tratamiento que las utilizan
US20070004635A1 (en) 2005-06-02 2007-01-04 Schering Corporation Method of treating interferon non-responders using HCV protease inhibitor
CA2611145A1 (en) 2005-06-02 2006-12-07 Schering Corporation Controlled-release formulation useful for treating disorders associated with hepatitis c virus
US20060287248A1 (en) 2005-06-02 2006-12-21 Schering Corporation Asymmetric dosing methods
US20060281689A1 (en) 2005-06-02 2006-12-14 Schering Corporation Method for modulating activity of HCV protease through use of a novel HCV protease inhibitor to reduce duration of treatment period
EP1891089B1 (en) 2005-06-02 2014-11-05 Merck Sharp & Dohme Corp. HCV protease inhibitors in combination with food
US20060276407A1 (en) 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis C virus
US7601686B2 (en) 2005-07-11 2009-10-13 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI389908B (zh) 2005-07-14 2013-03-21 Gilead Sciences Inc 抗病毒化合物類
TW200738742A (en) 2005-07-14 2007-10-16 Gilead Sciences Inc Antiviral compounds
TWI387603B (zh) 2005-07-20 2013-03-01 Merck Sharp & Dohme Ｈｃｖ ｎｓ３蛋白酶抑制劑
JP2009501732A (ja) 2005-07-20 2009-01-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎インヒビターペプチド類似体
KR101294467B1 (ko) 2005-07-25 2013-09-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 거대고리형 억제제
US8183277B2 (en) 2005-07-29 2012-05-22 Tibotec Pharmaceuticals Ltd. Macrocylic inhibitors of hepatitis C virus
PE20070343A1 (es) 2005-07-29 2007-05-12 Medivir Ab Inhibidores macrociclicos del virus de la hepatitis c
JO2768B1 (en) 2005-07-29 2014-03-15 تيبوتيك فارماسيوتيكالز ليمتد Large cyclic inhibitors of hepatitis C virus
ES2456617T3 (es) 2005-07-29 2014-04-23 Janssen R&D Ireland Inhibidores macrocíclicos del virus de la hepatitis C
ES2359939T3 (es) 2005-07-29 2011-05-30 Tibotec Pharmaceuticals Inhibidores macrocíclicos del virus de la hepatitis c.
AU2006274861B2 (en) 2005-07-29 2012-11-08 Medivir Ab Macrocyclic inhibitors of hepatitis C virus
RU2441870C2 (ru) 2005-07-29 2012-02-10 Тиботек Фармасьютикалз Лтд. Макроциклические ингибиторы вируса гепатита с
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
PE20070210A1 (es) 2005-07-29 2007-04-16 Tibotec Pharm Ltd Compuestos macrociclicos como inhibidores del virus de hepatitis c
PT1912997E (pt) 2005-07-29 2011-12-19 Tibotec Pharm Ltd Inibidores macrocíclicos do vírus da hepatite c
RU2419619C2 (ru) 2005-07-29 2011-05-27 Медивир Аб Макроциклические ингибиторы вируса гепатита с
EP1915382A2 (en) 2005-08-01 2008-04-30 Phenomix Corporation Hepatitis c serine protease inhibitors and uses therefor
JP4705984B2 (ja) 2005-08-01 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション Ｈｃｖｎｓ３プロテアーゼ阻害剤としての大環状ペプチド
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
DE602006019323D1 (de) 2005-10-11 2011-02-10 Intermune Inc Verbindungen und verfahren zur inhibierung der replikation des hepatitis-c-virus
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8268776B2 (en) 2006-06-06 2012-09-18 Enanta Pharmaceuticals, Inc. Macrocylic oximyl hepatitis C protease inhibitors
US7635683B2 (en) 2006-08-04 2009-12-22 Enanta Pharmaceuticals, Inc. Quinoxalinyl tripeptide hepatitis C virus inhibitors
US7605126B2 (en) 2006-08-11 2009-10-20 Enanta Pharmaceuticals, Inc. Acylaminoheteroaryl hepatitis C virus protease inhibitors
US7582605B2 (en) 2006-08-11 2009-09-01 Enanta Pharmaceuticals, Inc. Phosphorus-containing hepatitis C serine protease inhibitors
US20080279821A1 (en) 2007-04-26 2008-11-13 Deqiang Niu Arylpiperidinyl and arylpyrrolidinyl macrocyclic hepatitis c serine protease inhibitors
US8202996B2 (en) * 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20090285773A1 (en) 2008-05-15 2009-11-19 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20090285774A1 (en) 2008-05-15 2009-11-19 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2300491B1 (en) 2008-05-29 2016-01-06 Bristol-Myers Squibb Company Hepatitis c virus inhibitors

Also Published As

Publication number Publication date
PE20170534A1 (es) 2017-05-11
JP2011507869A (ja) 2011-03-10
CN101903371A (zh) 2010-12-01
EP2231639B1 (en) 2015-04-01
SI2231639T1 (sl) 2015-11-30
CL2008003849A1 (es) 2009-05-29
US20120230949A1 (en) 2012-09-13
AU2008343423A1 (en) 2009-07-09
EP2231639A1 (en) 2010-09-29
PL2231639T3 (pl) 2015-09-30
CN103755784A (zh) 2014-04-30
KR101560428B1 (ko) 2015-10-15
PT2231639E (pt) 2015-06-03
AR106338A2 (es) 2018-01-03
HRP20150458T1 (hr) 2015-06-05
US20090202476A1 (en) 2009-08-13
CN103755784B (zh) 2017-04-12
AU2008343423B2 (en) 2013-10-10
ES2536409T3 (es) 2015-05-25
TWI496573B (zh) 2015-08-21
DK2231639T3 (en) 2015-07-06
CN106146613A (zh) 2016-11-23
KR20100099703A (ko) 2010-09-13
US8338606B2 (en) 2012-12-25
WO2009085659A1 (en) 2009-07-09
MX336329B (es) 2016-01-15
JP5566907B2 (ja) 2014-08-06
TW200932214A (en) 2009-08-01
MX2010006489A (es) 2010-07-05
CN101903371B (zh) 2014-03-19
PE20131130A1 (es) 2013-10-05
US8202996B2 (en) 2012-06-19
AR069886A1 (es) 2010-02-24

Similar Documents

Publication Publication Date Title
PE20091217A1 (es) Formas cristalinas de n-(terc-butoxicarbonil)-3-metil-l-valil-(4r)-4-((7-cloro-4-metoxi-1-isoquinolinil)oxi)-n-((1r,2s)-1-((ciclopropilsulfonil)carbamoil)-2-vinilciclopropil)-l-prolinamida
CU20040029A7 (es) Cristales anhidros que incluyen una sal del ácido málico de una 2-indolinona sustituida con 3-pirrol, métodos de preparación y composiciones que las contienen
PE20120776A1 (es) Estructuras cristalinas de dapagliflozin y sus procesos de preparacion
CL2009001554A1 (es) Compuestos derivados de 4-(sulfonilaminoalquilamino)-n-fenil-n'-hidroxi-1,2,5-oxadiazol-3-carboximidamida; formas cristalinas; procesos de preparacion; compuestos intermediarios; composicion farmaceutica; y su uso para el tratamiento de enfermedades tales como cancer, infeccion viral, depresion, entre otras.
PE20090696A1 (es) Formas cristalinas de saxagliptina y procesos para preparar las mismas
AR059596A1 (es) Formas cristalinas anhidras y solvatadas de n-(benzo[b]tien-3-ilmetil)sulfamida.
CL2009000394A1 (es) Compuestos derivados de n-(1h-indazol-5-il)pirrolidin-3-carboxamida sustituida, inhibidores de erk; composicion farmaceutica; y su uso en el tratamiento del cancer.
AR053412A1 (es) Compuestos inhibidores de la interaccion entre mdm2 y p53, un metodo de preparadcion, composicion farmaceutica y uso del compuesto para fabricar medicamentos
CO6251311A2 (es) Proceso para la preparacion de acido 5-bifenil-4-amino-2-metil pentanoico
GT200600086A (es) Forma cristalina de gamma-d del clorhidrato de ivabradina, su procedimiento de preparación y composiciones farmacéuticas que la contienen
ECSP11010877A (es) Combinación de inhibidor de la proteasa ns3 de hcv con interferón y ribavirina
PE20090519A1 (es) Composicion farmaceutica que contiene n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)-etil]-amino]-metil]-fenil]-2e-2-propenamida
PE20121432A1 (es) Combinaciones de un inhibidor especifico de ns5a del hcv e inhibidor de proteasa ns3 del hcv
PE20140038A1 (es) Compuestos antivirales
CL2008001921A1 (es) Compuestos derivados de heterociclos sustituidos; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como ictus, isquemia cerebral, alzheimer, dolor, entre otras.
PE20081251A1 (es) Formas cristalinas del acido (3s)-3-[n-(n'-(2-terc-butilfenil)oxamil)alaninil]amino-5-(2',3',5',6'-tetrafluorofenoxi)-4-oxopentanoico
PE20130183A1 (es) Fosforamidatos de nucleosido
AR054347A1 (es) Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
PE20060602A1 (es) Derivados de heteroaril acil pirrolidina como inhibidores del virus de la hepatitis c (hcv)
CL2012003526A1 (es) Forma cristalina de clorhidrato de 1-(4-metoxibutil)-n-(2-metilpropil)-n-[(3s,5r)-5-(morfolin-4-ilcarbonil)piperidin-3-il]-1h-bencimidazol-2-carboxamida, inhibidor de renina; composicion farmaceutica; y uso en la profilaxis o tratamiento de una enfermedad circulatoria, enfermedad renal y de la hipertension.
EP1962843A4 (en) USE OF PARP-1 INHIBITORS
UY28248A1 (es) Compuestos quinicos
ECSP088153A (es) Nuevos derivados de piperidina
GT200600039A (es) Tiazolidinonas, su preparacion y su uso como medicamento
PE20120249A1 (es) Compuestos etanaminicos

Legal Events

Date Code Title Description
FC Refusal